September 7 is World Duchenne Awareness Day: Spreading Duchenne Muscular Dystrophy Awareness
source: pixabay.com

September 7 is World Duchenne Awareness Day: Spreading Duchenne Muscular Dystrophy Awareness

September 7, 2021 will be recognized as World Duchenne Awareness Day. This day will be set aside in recognition of awareness surrounding Duchenne muscular dystrophy, a rare and debilitating genetic…

Continue Reading September 7 is World Duchenne Awareness Day: Spreading Duchenne Muscular Dystrophy Awareness
Webinar: Using the Rare Disease Cures Accelerator for a DMD Progression Model
source: pixabay.com

Webinar: Using the Rare Disease Cures Accelerator for a DMD Progression Model

On July 21, 2021, Patient Worthy attended an online webinar presentation titled "How RDCA-DAP Can Help Inform Optimal Trial Design in Progressive Rare Disease." Organized by the Critical Path Institute…

Continue Reading Webinar: Using the Rare Disease Cures Accelerator for a DMD Progression Model
Experimental Duchenne Muscular Dystrophy Treatment Earns Rare Pediatric Disease Designation
source: pixabay.com

Experimental Duchenne Muscular Dystrophy Treatment Earns Rare Pediatric Disease Designation

According to a story from apnews.com, the biopharmaceutical company FibroGen, Inc., has recently announced that its investigational treatment pamrevlumab has earned Rare Pediatric Disease designation from the US Food and…

Continue Reading Experimental Duchenne Muscular Dystrophy Treatment Earns Rare Pediatric Disease Designation
Investigative Therapy for Duchenne Muscular Dystrophy is in a Phase 3 Clinical Trial
Source: Pixabay

Investigative Therapy for Duchenne Muscular Dystrophy is in a Phase 3 Clinical Trial

FibroGen has just announced that their investigative therapy pamrevlumab, for Duchenne muscular dystrophy (DMD), has received Rare Pediatric Disease designation from the FDA. The treatment already was given Fast Track…

Continue Reading Investigative Therapy for Duchenne Muscular Dystrophy is in a Phase 3 Clinical Trial
SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial
source: pixabay.com

SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial

Since its inception, life sciences company Solid Biosciences Inc. has been working to develop treatment options for patients with Duchenne muscular dystrophy (DMD). According to a recent press release, the…

Continue Reading SGT-001 Safety and Efficacy Data Available from IGNITE DMD Clinical Trial
This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD
mohamed_hassan / Pixabay

This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD

Pamrevlumab is a first-in-class antibody that treats Duchenne muscular dystrophy (DMD) by inhibiting the effects and activity of connective tissue disorder growth factor (CTGF). It is being developed by FibroGen,…

Continue Reading This Phase 3 Study Will Evaluate Pamrevlumab as a Treatment for DMD

Updates Available on Givinostat Clinical Development for DMD

During the virtual XVIII International Conference on Duchenne and Becker Muscular Dystrophy, specialty pharmaceutical company Italfarmaco Group ("Italfarmaco") shared updates regarding various Givinostat clinical development programs. The treatment is designed…

Continue Reading Updates Available on Givinostat Clinical Development for DMD

The First Duchenne Muscular Dystrophy Patient Receives Gene Therapy Treatment in Pfizer’s Phase 3 Trial

The very first patient has just been dosed in Pfizer's Phase 3 clinical trial for Duchenne muscular dystrophy (DMD). The trial is called CIFFREO. This patient received the therapy at a…

Continue Reading The First Duchenne Muscular Dystrophy Patient Receives Gene Therapy Treatment in Pfizer’s Phase 3 Trial